Heptares Therapeutics Ltd has entered into an option agreement with the Novartis Option Fund under which the UK company will make its technology available to Novartis to generate drug leads against an unspecified GPCR target. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
